Skip to main content

Search Results - life+sciences+%3e+therapeutics

181 Results Sort By:
Neuronal nitric oxide synthase (nNOS) inhibitors for targeted therapy of melanoma and neurodegenerative disorders
NU 2025-113 (NU 2016-137, NU 2018-176, NU 2019-179, NU 2023-007, NU 2024-250, NU 2025-038) INVENTORS Richard Silverman (Weinberg College of Arts and Sciences, Department of Chemistry) SHORT DESCRIPTION Novel highly selective neuronal nitric oxide synthase (nNOS) inhibitors for targeted therapy of melanoma and other cancers with high expression...
Published: 4/1/2026   |   Updated: 4/1/2026   |   Inventor(s):  
Keywords(s): ALS - Amyotrophic Lateral Sclerosis, AUTM26C1, BIAUTM1, Cancer/Oncology, Cardiology and Cardiovascular disease, Immunodeficiency, Immunology, Immunotherapy, Melanoma, Neurodegenerative disease, Neuroinflammation, nNOS, Small molecule, Targeted therapy, Therapeutics
Category(s): Life Sciences > Therapeutics
Targeting EGFR Co-Amplified Long-Noncoding RNA for Glioblastoma Treatment
NU 2025-335 INVENTORS Shi-Yuan Cheng* Xiaozhou Yu Bo Hu Runxin Wu Xiao Song SHORT DESCRIPTION This invention provides compositions and methods for inhibiting ELDR and HELDR, two long non-coding RNAs (lncRNAs) that are frequently co-amplified in glioblastoma (GBM) with the epidermal growth factor receptor (EGFR) gene, and which drive tumorigenesis...
Published: 3/30/2026   |   Updated: 3/30/2026   |   Inventor(s):  
Keywords(s): Brain cancer, Cancer Treatment, Cancer/Oncology, Therapeutics
Category(s): Life Sciences > Therapeutics
Noninvasive brain-specific inhibition of bone morphogenetic protein signaling for the prevention of tauopathy
NU2025-330 INVENTORS John Kessler* Justin Geier Chian-Yu Peng SHORT DESCRIPTION This invention uses a noninvasive gene therapy approach to prevent and treat tauopathies, such as Alzheimer's disease and frontotemporal dementia, by inhibiting bone morphogenetic protein (BMP) specifically within the central nervous system. BACKGROUND Tauopathies...
Published: 3/27/2026   |   Updated: 3/26/2026   |   Inventor(s):  
Keywords(s): AD - Alzheimer’s Disease, Gene therapy, Therapeutics
Category(s): Life Sciences > Therapeutics
Targeted pH Sensitive Liposomes
NU 2020-170 INVENTORS Leo Gordon* Dong-Hyun Kim* Shuo Yang Wooram Park Taehoon Sim SHORT DESCRIPTION Liposomal nanoparticles composed of pH-sensitive lipids and apolipoprotein that encapsulate andrographolide for lymphoma treatment. BACKGROUND Lymphoma, particularly diffuse large B-cell lymphoma (DLBCL), is the most common aggressive type...
Published: 3/11/2026   |   Updated: 3/11/2026   |   Inventor(s):  
Keywords(s): Blood & Lymphatic disease, Cancer/Oncology, Nanoparticle, Therapeutics
Category(s): Life Sciences > Therapeutics
Aminopyrimidine-based Kinase Inhibitors for Treatment of Cancer
NU 2015-098 Inventors Leonidas C. Platanias* Gary E. Schiltz Rama K. Mishra Short Description A small molecule to treat glioblastoma multiforme by blocking the Mnk pathway. Background Glioblastoma multiforme (GBM) is an aggressive brain cancer associated with a low survival rate, high recurrence, and limited therapeutic options. Most diagnosed...
Published: 3/5/2026   |   Updated: 3/5/2026   |   Inventor(s):  
Keywords(s): AD - Alzheimer’s Disease, Cancer/Oncology, Small molecule, Therapeutics
Category(s): Life Sciences > Therapeutics
Covalent PRC2 Inhibitors for Advanced Cancer Therapeutics
SHORT DESCRIPTION Covalent inhibitors and proteolysis-targeting chimera (PROTAC) degraders targeting components of the PRC2 complex (EZH and EED) to block both enzymatic and non-enzymatic functions, offering robust anti-tumor efficacy. INVENTORS Gary Schiltz (Weinberg College of Arts and Sciences, Department of Chemistry)* Jindan...
Published: 4/7/2026   |   Updated: 3/5/2026   |   Inventor(s):  
Keywords(s): AUTM26C1, BIAUTM1, Bladder cancer, Breast cancer, Cancer/Oncology, Covalent inhibitor, Lymphoma, Melanoma, PreSeed/Seed, Prostate cancer, PROTAC, Small molecule, Targeted protein degradation, Targeted therapy, Therapeutics
Category(s): Life Sciences > Therapeutics
Inhibition of BACH1 for pulmonary arterial hypertension therapy
LU 2024-222 INVENTORS Youyang Zhao* SHORT DESCRIPTION This invention identifies a protein called BACH1 as a key driver of pulmonary arterial hypertension (PAH). By targeting and inhibiting BACH1, particularly in the pulmonary endothelium, this technology provides methods for preventing or reversing the abnormal thickening of pulmonary vasculature,...
Published: 3/5/2026   |   Updated: 3/5/2026   |   Inventor(s):  
Keywords(s): Cardio-Pulmonary, Pulmonary disease, Targeted therapy, Therapeutics
Category(s): Life Sciences > Therapeutics
Antibodies for treatment of coronavirus disease
NU 2023-247 INVENTORS Huiping Liu* Deyu Fang* Hannah Mubarak Andrew Hoffmann Nurmaa Dashzeveg Lamiaa El-Shennawy Juncheng Wei Wuwei Tan Yang Shen SHORT DESCRIPTION Computationally redesigned antibodies targeting SARS-CoV-2 for treating COVID-19. BACKGROUND The continuous evolution of SARS-CoV-2 has allowed the virus to escape most therapeutic...
Published: 2/26/2026   |   Updated: 2/26/2026   |   Inventor(s):  
Keywords(s): Antibody, Artificial Intelligence & Machine Learning, Biologic, Infectious disease, Research tool, Targeted therapy, Therapeutics
Category(s): Life Sciences > Therapeutics
Aqueous Formulations of Cytotoxic Taxanes with Cyclodextrin
NU 2022-109 INVENTORS Brittney Williams Matthew Thompson Nathan Gianneschi* SHORT DESCRIPTION This invention describes aqueous formulations of cytotoxic taxane drugs conjugated to fatty acids, solubilized using cyclodextrin inclusion complexes, providing water-soluble chemotherapy formulations that eliminate the need for toxic organic solvents...
Published: 2/26/2026   |   Updated: 2/25/2026   |   Inventor(s):  
Keywords(s):  
Category(s): Life Sciences > Therapeutics
Methods of Using Modified Cytotoxins to Treat Cancer
NU 2019-135 INVENTORS Nathan Gianneschi* SHORT DESCRIPTION Methods for treating cancers that overexpress fatty acid uptake proteins using small-molecule cytotoxic drugs conjugated to long-chain fatty acid moieties. See also NU2022-111 and NU2022-109. BACKGROUND While prior work (under NU2022-111) demonstrated that lipid-mimicking cytotoxin...
Published: 2/26/2026   |   Updated: 2/25/2026   |   Inventor(s):  
Keywords(s): Cancer/Oncology, Small molecule, Therapeutics
Category(s): Life Sciences > Therapeutics
1 2 3 4 5 6 7 8 9 10 ...